The ras-oncogene-encoded p21 proteins, known to be critical in regulation of the cell cycle, are activated by binding GTP and/or by substitutions of amino acids at critical positions such as at Gly 12 and Gln 61. The latter substitutions cause the protein to become oncogenic and to undergo significant conformational changes. Conformational analysis (based on the program ECEPP) in which the low energy (hence observed) conformations of residues 4-18 and 55-67 for the """"""""normal"""""""" and substituted peptides were computed suggested that oncogenic substitutions cause significant local conformational changes in the peptides. The effects of these local conformational changes on the structure of the whole protein will be assessed by generating them into recent x-ray crystallographic structures for the p21 protein and minimizing the energy of the resulting structures using a new method to avoid local energy minimum """"""""traps"""""""". The purpose is to determine which region(s) of the protein undergo major structural changes in the presence of GDP and GTP. These calculations have already been performed on the Val 12-containing p21 protein. It was found that the Gln 61 region and the region from residues 32-47 known to bind to a putative target protein GTPase activating protein (GAP) undergo major conformational changes. These results have been corroborated in recent x- ray crystal structures. The significance of the conformational changes in the p21 protein will be related to cell transformation by identifying possible effector regions of the protein that may be involved in interacting with intracellular """"""""target"""""""" proteins by introducing a photoaffinity-labelled p21 protein into NIH 3T3 cells using red cell fusion. Proteins with which p21 may interact can be covalently labelled, isolated and identified by immunoprecipitation, SDS-PAGE and microsequencing. The regions of the p21 protein that are involved in the interactions can be identified by peptide mapping and amino acid analysis of the photoaffinity-labelled protein. The computed effects of the conformational changes in the protein on these identified regions will be explored. Possible amino acid substitutions that would block computed critical conformational changes in effector-binding segments will be determined and the prediction tested in site-specific mutagenesis and microinjection experiments. In addition, peptides from the putative effector regions of p21 will be synthesized and tested for their ability to block ras-induced cell transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042500-06
Application #
3183936
Study Section
Chemical Pathology Study Section (CPA)
Project Start
1988-09-30
Project End
1994-03-31
Budget Start
1992-04-01
Budget End
1993-03-31
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Upstate Medical University
Department
Type
Schools of Medicine
DUNS #
058889106
City
Syracuse
State
NY
Country
United States
Zip Code
13210
Sarafraz-Yazdi, Ehsan; Bowne, Wilbur B; Adler, Victor et al. (2010) Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci U S A 107:1918-23
Deng, Lili; Boujdir, Mohamed; Tremontano, Anthony et al. (2009) A peptide from a ras effector-domain blocks ras-dependent cardiac hypertrophy in myocytes. Ann Clin Lab Sci 39:351-60
Bowne, Wilbur B; Sookraj, Kelley A; Vishnevetsky, Michael et al. (2008) The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol 15:3588-600
Bowne, Wilbur B; Michl, Josef; Bluth, Martin H et al. (2007) Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer. Cancer Ther 5B:331-344
Qu, Yongxia; Adler, Victor; Chu, Tearina et al. (2006) Two dual specificity kinases are preferentially induced by wild-type rather than by oncogenic RAS-P21 in Xenopus oocytes. Front Biosci 11:2420-7
Michl, Josef; Scharf, Bruce; Schmidt, Anna et al. (2006) PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer 119:1577-85
Chie, Lyndon; Chung, Denise; Pincus, Matthew R (2005) Specificity of inhibition of ras-p21 signal transduction by peptides from GTPase activating protein (GAP) and the son-of sevenless (SOS) ras-specific guanine nucleotide exchange protein. Protein J 24:253-8
Smith, Steven; Hyde, Mark; Pincus, Matthew R (2005) Comparison of the predicted structures of loops in the ras-SOS protein bound to a single ras-p21 protein with the crystallographically determined structures in SOS bound to two ras-p21 proteins. Protein J 24:391-8
Adler, Victor; Qu, Yongxia; Smith, Steven J et al. (2005) Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 44:10784-95
Rosal, Ramon; Brandt-Rauf, Paul; Pincus, Matthew R et al. (2005) The role of alpha-helical structure in p53 peptides as a determinant for their mechanism of cell death: necrosis versus apoptosis. Adv Drug Deliv Rev 57:653-60

Showing the most recent 10 out of 98 publications